• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Nature and importance of follicular lymphoma precursors.滤泡性淋巴瘤前驱病变的本质与重要性。
Haematologica. 2014 May;99(5):802-10. doi: 10.3324/haematol.2013.085548.
2
Early lesions of follicular lymphoma: a genetic perspective.滤泡性淋巴瘤的早期病变:遗传学视角
Haematologica. 2014 Mar;99(3):481-8. doi: 10.3324/haematol.2013.094474. Epub 2013 Oct 25.
3
The routes for transformation of follicular lymphoma.滤泡性淋巴瘤的转化途径。
Curr Opin Hematol. 2016 Jul;23(4):385-91. doi: 10.1097/MOH.0000000000000255.
4
Emerging issues after the recognition of in situ follicular lymphoma.原位滤泡性淋巴瘤确诊后的新问题。
Leuk Lymphoma. 2014 Mar;55(3):482-90. doi: 10.3109/10428194.2013.807926. Epub 2013 Jul 15.
5
Premalignant cell dynamics in indolent B-cell malignancies.惰性B细胞恶性肿瘤中的癌前细胞动力学
Curr Opin Hematol. 2015 Jul;22(4):388-96. doi: 10.1097/MOH.0000000000000159.
6
Critical influences on the pathogenesis of follicular lymphoma.滤泡性淋巴瘤发病机制的关键影响因素。
Blood. 2018 May 24;131(21):2297-2306. doi: 10.1182/blood-2017-11-764365. Epub 2018 Apr 17.
7
Pathology of follicular lymphoma.滤泡性淋巴瘤的病理学
J Clin Exp Hematop. 2014;54(1):3-9. doi: 10.3960/jslrt.54.3.
8
Follicular lymphoma grade 3: review and updates.滤泡性淋巴瘤3级:综述与更新
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):431-5. doi: 10.1016/j.clml.2014.04.008. Epub 2014 Jun 12.
9
New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.滤泡性淋巴瘤生物学的新概念:从 BCL2 到表观遗传调节剂和非编码 RNA。
Semin Oncol. 2018 Oct;45(5-6):291-302. doi: 10.1053/j.seminoncol.2018.07.005. Epub 2018 Oct 23.
10
From genetics to the clinic: a translational perspective on follicular lymphoma.从遗传学角度到临床:滤泡性淋巴瘤的转化观点。
Nat Rev Cancer. 2018 Apr;18(4):224-239. doi: 10.1038/nrc.2017.127. Epub 2018 Feb 9.

引用本文的文献

1
Molecular Biomarkers in Prediction of High-Grade Transformation and Outcome in Patients with Follicular Lymphoma: A Comprehensive Systemic Review.分子生物标志物在预测滤泡性淋巴瘤患者高级别转化和结局中的作用:一项全面的系统性综述。
Int J Mol Sci. 2024 Oct 17;25(20):11179. doi: 10.3390/ijms252011179.
2
Oral squamous cell carcinoma with synchronous follicular lymphoma: A rare case report.口腔鳞状细胞癌合并同步滤泡性淋巴瘤:一例罕见病例报告。
SAGE Open Med Case Rep. 2024 Feb 27;12:2050313X241233423. doi: 10.1177/2050313X241233423. eCollection 2024.
3
The clinical and molecular taxonomy of t(14;18)-negative follicular lymphomas.t(14;18)阴性滤泡性淋巴瘤的临床和分子分类。
Blood Adv. 2023 Sep 26;7(18):5258-5271. doi: 10.1182/bloodadvances.2022009456.
4
Precursory or early lesions of follicular lymphoma: clinical features, pathology, and genetics.滤泡性淋巴瘤的前驱或早期病变:临床特征、病理学和遗传学。
J Clin Exp Hematop. 2023;63(2):65-72. doi: 10.3960/jslrt.23010.
5
Disease-Defining Molecular Features of Primary Cutaneous B-Cell Lymphomas: Implications for Classification and Treatment.原发性皮肤 B 细胞淋巴瘤的疾病定义分子特征:对分类和治疗的影响。
J Invest Dermatol. 2023 Feb;143(2):189-196. doi: 10.1016/j.jid.2022.07.027. Epub 2022 Sep 24.
6
"Double hit" B-lymphoblastic lymphoma with concurrent / and 8q24/ translocations: a case report.伴有并发8q24易位的“双打击”B淋巴细胞淋巴瘤:一例报告
Transl Cancer Res. 2021 Mar;10(3):1594-1598. doi: 10.21037/tcr-20-2748.
7
Follicular lymphoma: updates for pathologists.滤泡性淋巴瘤:给病理学家的最新资讯
J Pathol Transl Med. 2022 Jan;56(1):1-15. doi: 10.4132/jptm.2021.09.29. Epub 2021 Dec 27.
8
Germinal Center Cells Turning to the Dark Side: Neoplasms of B Cells, Follicular Helper T Cells, and Follicular Dendritic Cells.生发中心细胞走向黑暗面:B细胞、滤泡辅助性T细胞和滤泡树突状细胞肿瘤
Front Oncol. 2021 Jan 15;10:587809. doi: 10.3389/fonc.2020.587809. eCollection 2020.
9
Clonally related duodenal-type follicular lymphoma and follicular neoplasia.克隆相关的十二指肠型滤泡性淋巴瘤和滤泡性肿瘤。
Haematologica. 2019 Nov;104(11):e537-e539. doi: 10.3324/haematol.2019.226142. Epub 2019 Aug 1.
10
Unraveling Tumor Heterogeneity in an Apparently Monolithic Disease: BCL2 and Other Players in the Genetic Landscape of Nodal Follicular Lymphoma.解析看似单一疾病中的肿瘤异质性:BCL2及其他在结内滤泡性淋巴瘤基因格局中的参与者
Front Med (Lausanne). 2019 Mar 15;6:44. doi: 10.3389/fmed.2019.00044. eCollection 2019.

本文引用的文献

1
Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial.利妥昔单抗与观察等待策略在晚期无症状非大肿块滤泡淋巴瘤患者中的比较:一项开放标签随机 3 期试验。
Lancet Oncol. 2014 Apr;15(4):424-35. doi: 10.1016/S1470-2045(14)70027-0. Epub 2014 Mar 4.
2
Follicular lymphoma: watch and wait is watch and worry.滤泡性淋巴瘤:观察等待就是观察并担忧。
Lancet Oncol. 2014 Apr;15(4):368-9. doi: 10.1016/S1470-2045(14)70066-X. Epub 2014 Mar 4.
3
Genetics of follicular lymphoma transformation.滤泡性淋巴瘤转化的遗传学。
Cell Rep. 2014 Jan 16;6(1):130-40. doi: 10.1016/j.celrep.2013.12.027. Epub 2014 Jan 2.
4
Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.综合基因组分析鉴定出了推动滤泡性淋巴瘤发生和进展的反复突变和演化模式。
Nat Genet. 2014 Feb;46(2):176-181. doi: 10.1038/ng.2856. Epub 2013 Dec 22.
5
Early lesions of follicular lymphoma: a genetic perspective.滤泡性淋巴瘤的早期病变:遗传学视角
Haematologica. 2014 Mar;99(3):481-8. doi: 10.3324/haematol.2013.094474. Epub 2013 Oct 25.
6
Increasing genomic and epigenomic complexity in the clonal evolution from in situ to manifest t(14;18)-positive follicular lymphoma.在原位到表现为 t(14;18)阳性滤泡性淋巴瘤的克隆进化中,基因组和表观基因组复杂性增加。
Leukemia. 2014 May;28(5):1103-12. doi: 10.1038/leu.2013.307. Epub 2013 Oct 23.
7
Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120).无症状单克隆丙种球蛋白血症进展为骨髓瘤的临床、基因组和影像学预测因素(SWOG S0120)。
Blood. 2014 Jan 2;123(1):78-85. doi: 10.1182/blood-2013-07-515239. Epub 2013 Oct 21.
8
EZH2 mutations are frequent and represent an early event in follicular lymphoma.EZH2 突变频繁,是滤泡性淋巴瘤的早期事件。
Blood. 2013 Oct 31;122(18):3165-8. doi: 10.1182/blood-2013-04-496893. Epub 2013 Sep 19.
9
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi.利妥昔单抗维持治疗与观察对年龄大于 60 岁的晚期滤泡淋巴瘤患者一线 R-FND 化疗免疫联合利妥昔单抗巩固治疗后的影响:一项由意大利淋巴瘤基金会开展的 III 期随机研究。
J Clin Oncol. 2013 Sep 20;31(27):3351-9. doi: 10.1200/JCO.2012.44.8290. Epub 2013 Aug 19.
10
Follicular lymphoma-like B cells of uncertain significance (in situ follicular lymphoma) may infrequently progress, but precedes follicular lymphoma, is associated with other overt lymphomas and mimics follicular lymphoma in flow cytometric studies.意义未明的滤泡性淋巴瘤样 B 细胞(原位滤泡性淋巴瘤)可能偶尔会进展,但它先于滤泡性淋巴瘤发生,与其他明显的淋巴瘤有关,并在流式细胞术研究中模拟滤泡性淋巴瘤。
Haematologica. 2013 Oct;98(10):1571-80. doi: 10.3324/haematol.2013.085506. Epub 2013 Jul 5.

滤泡性淋巴瘤前驱病变的本质与重要性。

Nature and importance of follicular lymphoma precursors.

作者信息

Mamessier Emilie, Broussais-Guillaumot Florence, Chetaille Bruno, Bouabdallah Reda, Xerri Luc, Jaffe Elaine S, Nadel Bertrand

出版信息

Haematologica. 2014 May;99(5):802-10. doi: 10.3324/haematol.2013.085548.

DOI:10.3324/haematol.2013.085548
PMID:24790058
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4008113/
Abstract

It is now widely recognized that cancer development is a protracted process requiring the stepwise acquisition of multiple oncogenic events. In humans, this process can take decades, if not a lifetime, blurring the notion of 'healthy' individuals. Follicular lymphoma exemplifies this multistep pathway of oncogenesis. In recent years, variants of follicular lymphoma have been recognized that appear to represent clonal B-cell expansions at an early stage of follicular lymphoma lymphomagenesis. These include follicular lymphoma in situ, duodenal follicular lymphoma, partial involvement by follicular lymphoma, and in the blood circulating follicular lymphoma-like B cells. Recent genetic studies have identified similarities and differences between the early lesions and overt follicular lymphoma, providing important information for understanding their biological evolution. The data indicate that there is already genomic instability at these early stages, even in instances with a low risk for clinical progression. The overexpression of BCL2 in t(14;18)-positive B cells puts them at risk for subsequent genetic aberrations when they re-enter the germinal center and are exposed to the influences of activation-induced cytidine deaminase and somatic hypermutations. The emerging data provide a rationale for clinical management and, in the future, may identify genetic risk factors that warrant early therapeutic intervention.

摘要

现在人们普遍认识到,癌症发展是一个漫长的过程,需要逐步获得多种致癌事件。在人类中,这个过程可能需要数十年,如果不是一生的话,这模糊了“健康”个体的概念。滤泡性淋巴瘤就是这种多步骤肿瘤发生途径的例证。近年来,已认识到滤泡性淋巴瘤的变体,它们似乎代表滤泡性淋巴瘤淋巴瘤发生早期的克隆性B细胞扩增。这些包括原位滤泡性淋巴瘤、十二指肠滤泡性淋巴瘤、滤泡性淋巴瘤的部分受累以及血液中循环的滤泡性淋巴瘤样B细胞。最近的遗传学研究已经确定了早期病变与明显的滤泡性淋巴瘤之间的异同,为理解它们的生物学演变提供了重要信息。数据表明,即使在临床进展风险较低的情况下,这些早期阶段就已经存在基因组不稳定。t(14;18)阳性B细胞中BCL2的过表达使它们在重新进入生发中心并受到激活诱导的胞苷脱氨酶和体细胞超突变的影响时,有发生后续基因畸变的风险。新出现的数据为临床管理提供了理论依据,并且在未来,可能会确定需要早期治疗干预的遗传风险因素。